Difference between revisions of "Idecabtagene vicleucel (Abecma)"
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *3/26/2021: Approved for the treatment of adult patients with relapsed or refractory [[multiple myeloma]] after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. | + | *3/26/2021: Approved for the treatment of adult patients with relapsed or refractory [[multiple myeloma]] after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. ''(Approval based on KarMMa)'' |
== Patient Drug Information== | == Patient Drug Information== | ||
Revision as of 23:42, 17 April 2021
Mechanism of action
Anti-BCMA CAR T-cells.
Diseases for which it is used
History of changes in FDA indication
- 3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (Approval based on KarMMa)
Patient Drug Information
Also known as
- Code name: bb2121
- Generic name: ide-cel
- Brand name: Abecma